SUMMARY The history of cardiomyopathies over the past three decades is briefly surveyed and the definition of cardiomyopathy as "heart muscle disease of unknown cause" is reaffirmed. The recent slight modification of the classification based on disorders of structure and function into hypertrophic dilated (congestive) and restrictive/obliterature cardiomyopathy is underlined.
SUMMARY The history of cardiomyopathies over the past three decades is briefly surveyed and the definition of cardiomyopathy as "heart muscle disease of unknown cause" is reaffirmed. The recent slight modification of the classification based on disorders of structure and function into hypertrophic dilated (congestive) and restrictive/obliterature cardiomyopathy is underlined.
The hypothesis that hypertrophic cardiomyopathy results from abnormal catecholamine function in the developing heart is reviewed and supported. The concept of "obstruction" in hypertrophic cardiomyopathy is critically reviewed and challenged on the basis that true obstruction to outflow from the left ventricle is not present and that the pressure gradients often recorded are the result of elimination of the cavity of the ventricle as a result of powerful contraction of extensively hypertrophied muscle. The importance of impaired diastolic function with general and regional abnormalities of relaxation of a very complex nature is stressed. The natural history of hypertrophic cardiomyopathy is reviewed and the high incidence of sudden death confirmed in a personal series of over 250 patients studied over two decades. A relation between ventricular arrhythmia and sudden death has been noted. Studies of antiarrhythmic therapy disclosed that, while neither beta adrenergic blocking agents nor calcium blocking agents such as verapamil control arrhythmias studied by ambulatory tape monitoring, amiodarone is highly effective. It remains to be seen whether amiodarone will reduce the incidence of sudden death, the mechanism of which is discussed in the light of causes other than arrhytmia such as impairment of ventricular filling and reduction in left ventricular volume. A tentative scheme of treatment is suggested based on control of symptoms with beta adrenergic blocking agents and management of arrhythmias with amiodarone. The aetiologies of dilated congestive cardiomyopathy remain obscure. The possible place of virus infection leading to a disorder of cellular immunity is stressed.
Endomyocardial fibrosis as the leading cause of restrictive/obliterative cardiomyopathy is briefly described and the similarities in pathology and haemodynamics between endomyocardial fibrosis of the tropics and Loeffler's eosinophilic endomyocardial fibrosis are stressed. Evidence that the imature eosinophils found in patients with hypereosinophilic syndrome and endomyocardial disease can damage the endocardium is reviewed.
Finally, the involvement of cardiomyopathies in many fields of general internal medicine is stressed and it is suggested that no longer are the cardiomyopathies rare or curious diseases but relatively common disorders which are of interest to medical scientists in many fields and no longer the sole problem of the cardiologist.
Historical aspects delineation was imprecise. The cardiomyopathies were often confused with myocarditis, a term used Three decades ago the frontiers of cardiomyopathy widely in a variety of pathological and clinical con- were ill defined and nebulous because no working texts without clarity of expression: myocarditis was definition or classification had been suggested and sometimes equated with cardiomyopathy, sometimes with a specific inflammatory disorder.2 lecture on "uncommon myocardial diseases; the non coronary cardiomyopathies". 2 Brigden pointed out the diversity of the disorder and the difficulty of classification and was among the first to use the term "cardiomyopathy". Not surprisingly he regarded the cardiomyopathies as rare disorders which indeed they seemed to be at that time.
My interest was kindled by Brigden's approach and in 1%1 with colleagues Gordon, Hoilman, and Bishop our first paper was published defining cardiomyopathy and attempting a classification.3 The definition was clumsy but was slightly modified in a subsequent paper on cardiac function in primary myocardial disorders as follows: "cardiomyopathy: an acute, subacute or chronic disorder of heart muscle of unknown or obscure aetiology, often with associated endocardial or sometimes with pericardial involvement but not atherosclerotic in origin".4 At this time it was suggested that the term "primary myocardial disorder" should be used to describe those cardiomyopathies that were not the result of diseases in other parts of the heart, or elsewhere in the body; subsequently, in conjunction with Dr Celia Oakley, the definition of cardiomyopathy was simplified to "a disorder of cardiac muscle of unknown cause" while myocardial disorders that were part of a general systemic disease were termed "rare specific heart muscle diseases".5 Thus automatically any condition of which the cause or pathological process could be defined clearly was excluded from the definition of cardiomyopathy. This concept has not always been readily accepted but has received approval from the joint task force of the World Health Organisation and International Society and Federation of Cardiology on the definition and classification of cardiomyopathies. 6 The concept of a classification based upon the disorders of structure In addition to the hypertrophic, congestive, and constrictive types, a new group was introduced, that of obliterative cardiomyopathy, to indicate the effects of endomyocardial fibrosis in obliterating the cavity of the ventricle.'0 1 1 Recently, three further changes have been made in the classification in the light of increasing knowledge. First, the word "obstructive" has been omitted from the definition of hypertrophic obstructive cardiomyopathy, and this type has come to be known simply as hypertrophic cardiomyopathy.'Z'4 Second, the importance of ventricular dilatation in congestive cardiomyopathy has been recognised by the use of the word "dilated" in the definition. The term "congestive", which was introduced in 19613 at a time when diagnosis was seldom made before the development of florid congestive heart failure, is now felt to be inappropriate, especially as cases can now be recognised before overt congestive failure has occurred. Nevertheless, it is useful to retain the word "congestive" because it has become authenticated by frequent usage and its omission could cause confusion.
Third, the restrictive and obliterative types have been combined into one group (restrictive/ obliterative) because it is known that the obliteration is merely a late stage of the restrictive type (when resulting from endomyocardial fibrosis) and a separate obliterative group is therefore not warranted6 (Fig. 1) .
It is important to emphasise the terminology used. Elimination refers to disappearance of the ventricular cavity by compression and apposition of its walls. Angiocardiography shows almost complete or complete elimination of the apex and body of the left ventricle in systole in many cases and demonstrates the apposition of the mitral valve to the septum caused by the powerful contraction and the reduction in ventricular volume. The abnormal angulated shape of the left ventricle with massive papillary muscles of the mitral valve and massive hypertrophy of the septum and free wall is associated with greatly reduced left ventricular volume in systole (Fig. 3) . The cavity is virtually squeezed out of existence by the fierce contractile action of the increased muscle mass. Indeed the cavity of the left ventricle is neither obstructed nor obliterated, but rather is virtually eliminated.
Systolic anterior movement of the mitral valve apparatus and mid-systolic closure of the aortic valve are present when gradients are found.38 It is the papillary muscles rather than the cusp of the mitral valve, however, that meet the hypertrophied septum. 39 The apex of the left ventricle is eliminated by the powerfully contracting hypertrophied muscle mass (Fig. 4,  Fig. 5) .
Gradients, however, are important and should not be dismissed. They are diagnostically valuable; they warn that powerful inotropic agents, manoeuvres, or drugs that reduce ventricular volume can be dangerous; the presence of persistent gradients warns of possible associated fixed outflow tract obstruction requiring operation; and finally septal resection in selected patients can produce symptomatic relief though it does not improve prognosis.
I do not support the view of Gilbert Alvares46 in our laboratory using phonocardiography, apex cardiography, and M-mode echocardiography showed that the normal sequence of events in diastole is completely disrupted in hypertrophic cardiomyopathy. Aortic valve closure occurred after the minimum dimension of the left ventricular cavity, and the isovolumic relaxation period (from aortic valve closure to mitral valve opening), though often prolonged, tended to be shortened in patients with gradients (Fig. 6) . The effects of chronic beta adrenergic blockade were variable. In the majority of patients the active suction period was prolonged, thus aiding ventricular filling, but in the minority was shortened (Fig. 7) . These results indicate the variability and incoordination of ventricular diastolic function and thus the difficulty of predicting the effects of any particular drug. They also explain the diverse effects of beta adrenergic blockade.
It is apparent that the diastolic abnormalities in hypertrophic cardiomyopathy are the most important feature of the disease and are exceedingly complex. Far from being uniform, they are patchy and irregular, depending upon the extent and distribution of the myofibrillar lesions. Generalisations as to the exact disorder of the normal filling pattern in any individual patient are likely to be fallacious.
DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS OF HYPERTROPHIC CARDIOMYOPATHY
When gradients are present the diagnosis can be made at the bedside by three cardinal physical signs. The ejection murmur of late onset is heard at the apex, at the left sternal edge, and occasionally at the base of the heart. The arterial pulse shows a rapid upstroke and rapid decline and has an ill-sustained or jerky quality. The third sign is the palpable atnial beat caused by the strong contraction of the left atrium needed to fill the stiff left ventricle (Fig. 8) .
When gradients are present the differential diagnosis must include aortic valvar stenosis, subvalvar stenosis, mitral regurgitation, and ventricular septal defect but when the three major physical signs are present and when there is a family history of sudden death and symptoms of angina, dyspnoea, and syncope a diagnosis of hypertrophic cardiomyopathy can be made reliably at the bedside.
When gradients are absent and there is little if any murmur the diagnosis is much more difficult. The heart may even appear to be normal, though a palpable left atrial beat and jerky pulse are useful clues. Sometimes pulmonary hypertension may be noted because of the high left ventricular end-diastolic pressure.
When there is an apical mid-diastolic murmur, mitral valve disease or left atrial myxoma may be suggested, while when there is mitral valve calcification and atrial fibrillation the differentiation from rheumatic heart disease can often not be made clinically and depends upon angiocardiography. In (Fig. 3) . A detailed analysis of 100 of our patients showed that 90 had either elimination of the left ventricular cavity or pronounced narrowing of the mid portion of the ventricle, with angulation of the body. Sometimes contrast medium may be squeezed into the apex and almost isolated from the main cavity (Fig. 9) (Fig. 4) . The anterior mitral valve apparatus meets the septum and this is how gradients are created. The combination of resistance to filling of the left ventricle, reduced left ventricular volume, and powerful left ventricular contraction together cause a sudden dramatic fall in effective left ventricular outflow. This is the "obstruction" so frequently discussed (Fig. 4) Before deciding on the best form of treatment the patient should have a 48 or 72 hour ambulatory electrocardiographic study. If this indicates premature ventricular extrasystoles or runs of ventricular tachycardia then amiodarone should be given in a dose of 600 mg daily for one week, and then 400 daily. If the patient also has symptoms of dyspnoea and angina these may respond to amiodarone alone. If not, propranolol or another non selective beta blocking agent should be given cautiously in addition, starting with a small dose of 10 mg four times daily and increasing carefully. We do not yet have data on the results or risks of combined treatment with amiodarone or beta blockade, so caution is necessary. But theoretically this combination is attractive as it has the twin aims of improving prognosis and relieving symptoms.
If there are no arrhythmias, but symptoms are present, propranolol should be given as the sole drug. If beta adrenergic blocking therapy is not successful, verapamil may be tried. In some patients it certainly improves symptoms, haemodynamics, and exercise capacity,62 63 but other patients do badly, as we have noted. Hypotension and lengthening of the PR interval may occur on intravenous administration.6263 Rosing et al.64 were obliged to discontinue oral verapamil because of sinus arrest and hypotension in one patient after a single dose of 80 mg verapamil, while another patient developed second degree intraventricular block. Two additional patients died; one developed severe chest pain after four doses of 80 mg of verapamil and the other died during operation for septal resection, having previously developed pulmonary oedema on verapamil at a dose of 130 mg six hourly for 13 doses.
The long term effects of verapamil have also been studied. 64 It is tempting to hope that propranolol might reduce left ventricular hypertrophy by diminishing the force of contraction of the left ventricle. Though the work of Vaughan Williams et al. 66 showing reduction of rate of growth of the myocardium in small animals given propranolol, there is no clinical evidence to indicate that this happens in man with hypertrophic cardiomyopathy.
The place of other calcium blocking agents such as nifedipine and diltiazem is not known. Nifedipine has been shown to improve diastolic function in acute haemodynamic observations.67 Care should be taken with nifedipine because it can produce considerable vasodilatation and hypotension and could thus precipitate syncope.
SURGICAL TREATMENT
Septal resection is indicated in a small group of patients with persistent outflow tract gradients of greater than 50 mmHg, severe symptoms which do not respond to medical treatment, and pronounced septal and papillary muscle hypertrophy. The immediate results are gratifying in terms of relief of symptoms and improvement in haemodynamics but the mortality is high, and there is an incidence of late congestive heart failure after the operation.6869 Kuhn et Immediate cardioversion is required if rapid atrial fibrillation develops. Heparin should be given to prevent embolism. After conversion to sinus rhythm amiodarone may.be given as it is likely to maintain the patient in sinus rhythm, or, if not, to stabilise the atrial fibrillation. Alternatively, a small dose of digitalis may be given along with a small dose of beta adrenergic blocking agent. Amiodarone may be given in conjunction with digitalis but it tends to increase the effects of digitalis on the heart so caution is necessary. Congestive heart failure implies advanced and severe widespread disease that should be treated in the usual way with diuretics which must be used with great care in patients with persistent outflow tract gradients. Vasodilator therapy for heart failure is contraindicated.
When congestive heart failure develops, gradients usually disappear,9 but in some patients these may remain. Such patients are all too often intractable therapeutic problems; the risks of surgical treatment are very high and the results poor.
Much has been learned about hypertrophic cardiomyopathy over the past two decades. The impressions gained initially have been revised in the light of new knowledge. Clues as to prognosis are emerging and we can expect treatment to become more rational. The catecholamine theory of causation of hypertrophic cardiomyopathy, while not proven, has much theoretical, circumstantial, and some practical appeal.
Dilated congestive cardiomyopathy
This is a syndrome of dilated ventricles, gallop rhythm, and congestive heart failure, with gross impairment of systolic function. The clinical and haemodynamic improvement after graded doses of metoprolol. It has been suggested that patients with disproportionate tachycardia who may thus have an excess of catecholamines in the heart may be those most suitable for treatment, but a study from our department95 did not show any increase in plasma noradrenaline or in sympathetic function before overt heart failure had occurred, though parasympathetic function was impaired. Certainly slowing of the heart and reduction in oxygen demand might be of value. By contrast with the results of the Swedish investigators, Ikram and Fitzpatrick96 found no benefit from beta adrenergic blockade treatment, but many of their patients (71%) had possible alcoholic cardiomyopathy and were less severe symptomatically than the cases of Swedberg et al.94 In addition, they used a different agent, and the duration of treatment was shorter. The matter is still undecided and further trials are necessary.
The results of the studies by Mason et al. 85 suggest that when the duration of heart failure is short (a year or less) and the endomyocardial biopsy shows evidence of inflammatory action, steroids and immunosuppressive drugs may be of benefit. It has been suggested86 that the endocardium reacts in the same way to different irritants, producing the exudative reaction leading to fibrosis and thrombosis, with changes in the small intramyocardial vessels that is characteristic of endomyocardial fibrosis. Scarring of the myocardium results and in the late stages fibrous tissue and thrombus progressively obliterate the ventricular cacity and increase the resistance to inflow.
A possible irritant that has been extensively studied is the eosinophil. Clones of circulating eosinophils in Loeffler's endomyocardial disease have structural abnormalities. They are vacuolated and degranulated. The granules are abnormal and may release products which damage the endocardium. 99 There is abnormal binding of IgG coated erythrocytes. A third of the abnormal eosinophils ingest red blood cells that are coated with complement as compared with less than 1% in normal subjects. Also eosinophil kinetics are abnormal and their half life is twice normal. Prolonged retention of eosinophils in the drculation may be an important factor in endomyocardial damage.98 99 It may be that the rogue eosinophil is also the cause of tropical endomyocardial fibrosis and studies sponsored by the ISFC are in progress to investigate this. TREATMENT Although rare, amyloid heart disease is an intriguing entity. Because of its distribution around the small 15 blood vessels in the myocardium it produces a stiff unyielding muscle mass; the "stiff heart". 105 The rigid myocardium causes abnormalities of filling, some of which resemble constrictive pericarditis and restrictive cardiomyopathy. Differences do exist, however, especially in the pattern of ventricular filling. Filling is slow throughout diastole in contrast to endomyocardial fibrosis in which ventricular filling is initially rapid and then becomes slow. This difference explains the absence of a left ventricular third heart sound in amyloid heart disease. 105 Nevertheless, clinical similarities to constrictive pericarditis or restrictive cardiomyopathy do exist, especially in the pattern of the jugular venous pulse, and amyloid disease should be considered in the differential diagnosis especially if there is cardiac pain.
I have presented some hard data, much personal experience and conviction, and a deal of speculation. I make no apology for the last for it is the business of clinical research workers to ask questions as well as to answer them.
I speculate that hypertrophic cardiomyopathy is an endocrine disorder; that congestive cardiomyopathy is a disease of cellular immunity set up by a previous virus infection; that restrictive/obliterative cardiomyopathy is a disorder of immunity of the eosinophil.
There are many problems to be resolved and the prospects may seem daunting, yet they are, in fact, exciting and challenging and I am sure we will have the answers by the end of the century, though we shall require the collaboration of experts in many fields: immunologists, cell biologists, endocrinologists, biochemists, geneticists, and others.
No longer are the zardiomyopathies the province of the cardiologist alone for their frontiers extend deep into the realms of general internal medicine, pathology, and immunology. 
